Subcommittee on Neurological Disease committee  There would be a treatment arm.

Subcommittee on Neurological Disease committee  So again, I think we agree here that our health care system is based on evidence-based practice. We do not submit patients to treatments for which we don't have proof that it works and that the benefits outweigh the risks. That's the first thing. The second thing is what you're

Subcommittee on Neurological Disease committee  You have several questions. I think I will start by thanking you for making it clear that you believe that any treatment should be based on evidence and for having the confidence that CIHR can provide that evidence. Now obviously we can only fund proposals that are submitted to

Subcommittee on Neurological Disease committee  That's another piece to we're trying to do to accelerate the research in that area. For accelerating research in that area, we have to see the whole picture and put this proposal in the broader context of the relationships between cerebrospinal venous insufficiency and venous con

Subcommittee on Neurological Disease committee  Not necessarily with experience in treating patients with MS, but with experience in angioplasty, yes. So we need people with experience in imaging for diagnosing venous insufficiency, neurologists with experience with MS, and, of course, surgeons with experience with angioplasty

Subcommittee on Neurological Disease committee  Well, that's exactly...it's part of what we're asking this committee of experts: to analyze what's out there and what are the contradistinctions. As you saw, there are contradictions out there in the literature. We have to understand these contradictions, look at what's out there

Subcommittee on Neurological Disease committee  Thank you, Madam Chair. It is with great pleasure that I appear before you today in my role at the Canadian Institutes of Health Research to discuss the important issue of multiple sclerosis research in Canada. Your committee is holding important hearings on the matter, and I'm

Health committee  I cannot give a precise answer to that question because it hasn't been approved by Treasury Board yet. What I can tell you is that a portion of that $16 million will be invested in clinical trials and that we welcome applications to CIHR for clinical trials on MS. The deadline fo

Health committee  So the competition is open, the deadline for registration for a new clinical trial would be August 16, and the final proposal in the beginning of September.

Health committee  It's for open clinical trials, and any proposal for a clinical trial related to MS will be evaluated on the base--

Health committee  It is totally broad.

Health committee  I think we're looking at a two-phased approach here. Right now, as I said, we want to put part of the money—and it hasn't been approved yet, so I can't give you a specific number—out of the new $16 million in additional funds that we receive into clinical trials, and we are hopef

Health committee  It's more a shift in the organization of the presentation than a shift in priorities.

Health committee  No.

Health committee  We don't have that information here. I'd certainly be happy to forward you the information. It's really a re-shifting of the structuring of the presentation and where it falls.... I can make sure you get it. I just don't have it with me.